Back to Journals » OncoTargets and Therapy » Volume 11
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
9,591 | Dovepress* | 8,552+ | 799 | 9,351 | |
PubMed Central* | 1,039 | 265 | 1,304 | ||
Totals | 9,591 | 1,064 | 10,655 | ||
*Since 26 November 2018 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
6 | 0 | 0 | 1 | 2 | 3 |
View citations on PubMed Central and Google Scholar